177 related articles for article (PubMed ID: 35196635)
1. Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance.
Sun K; Li M; Shang M; Su X; Zhao J; Wang B; Wu C; Zhang L; Yang S; Sun X
Lung Cancer; 2022 Apr; 166():63-69. PubMed ID: 35196635
[TBL] [Abstract][Full Text] [Related]
2. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non-Small Cell Lung Cancer.
Hattori A; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
J Thorac Oncol; 2017 Jun; 12(6):954-962. PubMed ID: 28257958
[TBL] [Abstract][Full Text] [Related]
4. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
Sullivan I; Salazar J; Arqueros C; Andrés M; Sebio A; Majem M; Szafranska J; Martínez E; Páez D; López-Pousa A; Baiget M; Barnadas A
Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
[TBL] [Abstract][Full Text] [Related]
5. Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography.
Sun K; You A; Wang B; Song N; Wan Z; Wu F; Zhao W; Zhou F; Li W
Eur Radiol; 2021 Oct; 31(10):7353-7362. PubMed ID: 33860370
[TBL] [Abstract][Full Text] [Related]
6. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
Wang S; Zhang B; Qian J; Qiao R; Xu J; Zhang L; Zhao Y; Zhang Y; Wang R; Zhao R; Han B
Lung Cancer; 2018 Nov; 125():245-252. PubMed ID: 30429028
[TBL] [Abstract][Full Text] [Related]
7. Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?
Kim W; Lee SM; Lee JB; Seo JB; Kim HK; Kim J; Lee HY
Korean J Radiol; 2022 Mar; 23(3):370-380. PubMed ID: 35213098
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid or solid-dominant stage IA non-small cell lung cancer.
Rao S; Ye L; Min L; Zhao G; Chen Y; Huang Y; Yang J; Xiao S; Cao R
J Cardiothorac Surg; 2019 Nov; 14(1):197. PubMed ID: 31722726
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
12. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
13. Extent of mediastinal nodal dissection in stage I non-small cell lung cancer with a radiological pure-solid appearance.
Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
Eur J Surg Oncol; 2021 Jul; 47(7):1797-1804. PubMed ID: 33745792
[TBL] [Abstract][Full Text] [Related]
14. The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer.
Shoji F; Haratake N; Akamine T; Takamori S; Katsura M; Takada K; Toyokawa G; Okamoto T; Maehara Y
Anticancer Res; 2017 Feb; 37(2):741-747. PubMed ID: 28179325
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.
Fung AS; Kopciuk K; Dean ML; D'Silva A; Otsuka S; Klimowicz A; Hao D; Morris D; Bebb DG
PLoS One; 2021; 16(1):e0241240. PubMed ID: 33507926
[TBL] [Abstract][Full Text] [Related]
16. Nomograms for Predicting Overall and Recurrence-free Survival From Pathologic Stage IA and IB Lung Cancer After Lobectomy.
Merritt RE; Abdel-Rasoul M; Fitzgerald M; D'Souza DM; Kneuertz PJ
Clin Lung Cancer; 2021 Jul; 22(4):e574-e583. PubMed ID: 33234491
[TBL] [Abstract][Full Text] [Related]
17. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
18. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
[TBL] [Abstract][Full Text] [Related]
19. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
20. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
